A new task force comprising staff from the UK medicines regulator, the MHRA, and cost-effectiveness arbiter NICE – with the ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab which achieved significant ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Hikma's announcement ties into that sentiment, coming with the strap line: "America Leans on Hikma: Quality Medicines ...

Galapagos announces leadership transition. European biotechnology company Galapagos completed a significant leadership ...

In the case of the amyloid drugs, Eisai Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) – there are also ...

Shares in PolyPid have been under pressure after the Israeli biotech reported its antibiotic for surgical site infections failed a phase 3 trial, although there may still be a way forward for the ...

We need to broaden access to advanced technologies so that, ultimately, every patient can benefit from them. It’s a goal otherwise known as the “hyperscaling of healthcare”.

BioCryst has agreed to sell its European business based on hereditary angioedema (HAE) therapy Orladeyo to Italy's Neopharmed ...

GRIN-related neurodevelopmental disorder (GRIN-NDD) is a family of rare, genetically defined neurodevelopmental disorders ...

ASCO 2025 spotlighted new data across haematologic cancers this year. To discuss announcements in liquid cancers further, as opposed to solid tumours, pharmaphorum spoke with Dr Lore Gruenbaum, chief ...

Since the first-generation CAR-Ts reached the market several years ago, clinicians have become more adept at handling ...